oral, covalent MK2 inhibitor

Ph. II candidate in ankylosing spondylitis

from previously disclosed MK2 inhibitor and SBDD

Transl Res

Bristol Myers Squibb, Princeton, NJ

CC-99677 Chemical Structure oral, covalent MK2 inhibitor - Bristol Myers Squibb, Princeton, NJ

Context. CC-99677 (BMS) is an oral, covalent MAPK–activated protein kinase-2 (MK2) inhibitor being developed for autoimmune diseases. Although p38 is the most heralded member of the p38-MAPK signaling pathway,…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: